David M. Davidson

Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials

Stuart Johnson, Thomas Louie, Dale N. Gerding et al. · Clinical Infectious Diseases · 2014 · 508 citations · Full text

The Emerging Infectious Challenge of Clostridium difficile-Associated Disease in Massachusetts Hospitals: Clinical and Economic Consequences

Judith A. O’Brien, Betsy J. Lahue, J. Jaime et al. · Infection Control and Hospital Epidemiology · 2007 · 318 citations

NF-κB inhibition causes spontaneous apoptosis in Epstein–Barr virus-transformed lymphoblastoid cells

Ellen Cahir-McFarland, David M. Davidson, Stephanie L. Schauer et al. · Proceedings of the National Academy of Sciences · 2000 · 258 citations

Tolevamer, a Novel Nonantibiotic Polymer, Compared with Vancomycin in the Treatment of Mild to Moderately Severe Clostridium difficile-Associated Diarrhea

Thomas Louie, Jennifer Peppe, Chi‐Leung Watt et al. · Clinical Infectious Diseases · 2006 · 204 citations · Full text

Epstein–Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the IκB kinases IKKα and IKKβ

Bakary S. Sylla, Siu Chun Hung, David M. Davidson et al. · Proceedings of the National Academy of Sciences · 1998 · 155 citations · Full text